Cannabis, honestly — what the evidence says

Cannabis is increasingly legal and widely used — but it is neither harmless nor a cure-all. Here is what is actually supported, what is genuinely risky, and what is oversold, for THC and CBD separately.

THC vs CBD

THC is the intoxicating part — the "high", but also the anxiety and paranoia at higher doses. CBD is non-intoxicating and marketed for almost everything. They are very different compounds, and lumping them together is where a lot of the confusion (and marketing) lives.

What’s actually supported

• Specific medical uses — Real evidence for chemotherapy nausea, some chronic and nerve pain (modest), muscle spasticity in MS, and rare severe childhood epilepsy (a purified high-dose CBD medicine). These are specific, supervised uses — not the same as a gummy from a shop. (established)
• Short-term relaxation and euphoria — The recreational effects are real and short-lived. For some people they are pleasant; for others (especially with high-THC products) anxiety and paranoia dominate. (established)
• CBD for everyday anxiety or sleep — Human evidence at the low doses in consumer products is weak and mixed. The strong CBD evidence is for pharmaceutical doses in epilepsy — far higher than a shop-bought oil. (emerging)

The dependence risk

The dependence risk — an illustrative chart on this page. Figures use honest, cited or clearly-illustrative data; they are visual aids, not personal measurements.

The real risks

• Dependence is real — Roughly 1 in 10 users develop cannabis use disorder — higher with daily use or starting young. "Not addictive" is a myth. (established)
• Psychosis risk with high-potency use — Daily use of high-potency cannabis is linked to a substantially higher risk of psychotic disorder, especially in vulnerable young people — a key finding of the EU-GEI study across Europe. (established)
• The teenage brain — Heavier use in adolescence is associated with cognitive and mental-health harms; the developing brain is the most vulnerable window. (emerging)
• Driving impairment — THC measurably impairs reaction time and coordination; driving high is genuinely dangerous, and edibles make dosing and timing unpredictable. (established)

What’s oversold

• “CBD cures everything” — Most consumer CBD is under-dosed and lacks evidence for the sweeping claims (pain, anxiety, inflammation, sleep) made about it. (hype)
• “Natural, so it’s safe” — Potency has risen sharply and concentrates/vapes are strong. "Natural" says nothing about dose or risk. (hype)

What we still don’t know

• Long-term effects of today’s high-potency products Much older research used far weaker cannabis; the long-term picture for modern high-THC products and concentrates is still emerging.
• Who is vulnerable to the psychosis risk We know the population-level link but cannot yet reliably predict which individual is at risk.
• CBD’s real effect size Whether low-dose consumer CBD does anything beyond placebo for common complaints is genuinely unsettled.

Key terms

• THC The main intoxicating compound in cannabis — the "high", and the driver of most acute risks.
• CBD A non-intoxicating cannabis compound, widely marketed; strong evidence only at pharmaceutical doses in epilepsy.
• Cannabis use disorder Dependence on cannabis — problematic, hard-to-control use; affects roughly 1 in 10 users.
• Potency The THC concentration; modern products are far stronger than decades ago.